These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9591936)

  • 1. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer.
    Rentsch KM; Schwendener RA; Pestalozzi BC; Sauter C; Wunderli-Allenspach H; Hänseler E
    Eur J Clin Pharmacol; 1998 Mar; 54(1):83-9. PubMed ID: 9591936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
    Rentsch KM; Horber DH; Schwendener RA; Wunderli-Allenspach H; Hänseler E
    Br J Cancer; 1997; 75(7):986-92. PubMed ID: 9083333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide.
    Zhang L; Ren Y; Wang Y; He Y; Feng W; Song C
    Int J Nanomedicine; 2018; 13():1097-1105. PubMed ID: 29520138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
    Schwendener RA; Fiebig HH; Berger MR; Berger DP
    Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.
    Ahmad A; Wang YF; Ahmad I
    Methods Enzymol; 2005; 391():176-85. PubMed ID: 15721381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone- and Folate-TPGS2k Conjugate Hybrid Micellar Aggregates To Circumvent Toxicity and Enhance Efficiency for Breast Cancer Therapy.
    Guissi NE; Li H; Xu Y; Semcheddine F; Chen M; Su Z; Ping Q
    Mol Pharm; 2017 Apr; 14(4):1082-1094. PubMed ID: 28191959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
    Lu B; Xiong SB; Yang H; Yin XD; Chao RB
    Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of mitoxantrone.
    Ehninger G; Proksch B; Heinzel G; Woodward DL
    Cancer Treat Rep; 1986 Dec; 70(12):1373-8. PubMed ID: 3791250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux.
    Ling G; Zhang T; Zhang P; Sun J; He Z
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1351-9. PubMed ID: 26754913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.
    Orthmann A; Zeisig R; Süss R; Lorenz D; Lemm M; Fichtner I
    Pharm Res; 2012 Jul; 29(7):1949-59. PubMed ID: 22399388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
    Schleyer E; Kamischke A; Kaufmann CC; Unterhalt M; Hiddemann W
    Leukemia; 1994 Mar; 8(3):435-40. PubMed ID: 8127148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.
    Pedrosa LR; Ten Hagen TL; Süss R; van Hell A; Eggermont AM; Verheij M; Koning GA
    Pharm Res; 2015 Apr; 32(4):1354-67. PubMed ID: 25319103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and metabolism of mitoxantrone in man.
    Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
    Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.
    Lu B; Xiong SB; Yang H; Yin XD; Zhao RB
    Int J Pharm; 2006 Jan; 307(2):175-81. PubMed ID: 16314056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor cell targetability of folate receptor-mediated mitoxantrone albumin nanoparticles].
    Zhang LK; Hou SX; Mao SJ; Wei DP; Song XR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):77-9. PubMed ID: 16468648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics].
    Duan YS; Yu BT; Zhang ZR
    Yao Xue Xue Bao; 2002 Jun; 37(6):465-8. PubMed ID: 12579808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of mitoxantrone. A review.
    Ehninger G; Schuler U; Proksch B; Zeller KP; Blanz J
    Clin Pharmacokinet; 1990 May; 18(5):365-80. PubMed ID: 2185907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.